Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 8;11(3):475.
doi: 10.3390/diagnostics11030475.

Additional Value of [18F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis

Kota Yokoyama  1 , Junichi Tsuchiya  1 , Yuji Nakamoto  2 , Ukihide Tateishi  1
Affiliations

Additional Value of [18F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis

Kota Yokoyama et al. Diagnostics (Basel). .

Abstract

To assess the additional value of 2-deoxy-2-[18F] fluoro-d-glucose ([18F]FDG) positron emission tomography (PET) or PET/CT over conventional morphological imaging techniques in the treatment response assessment of gastrointestinal stromal tumor (GIST) to molecular targeted therapy (MTT), we performed a meta-analysis of all the available studies to compare the predictive value of [18F]FDG PET or PET/CT and conventional imaging techniques for assessing the response to MTT in GIST. We determined the sensitivities and specificities across studies, we calculated the positive and negative likelihood ratios (LR) and made summary receiver operating characteristic curves (SROC) using hierarchical regression models. Pooled analysis included 4 studies comprising 88 patients. The performance characteristics in [18F]FDG PET or PET/CT and CT were as follows: sensitivity, 89% (95% confidence interval (CI) 78, 95), 52% (39, 64); specificity, 65% (44, 83), 92% (75, 99); diagnostic odds ratios (DOR), 5.8 (2.0, 16.8 4.9 (1.5, 16.1); positive LR, 1.9 (1.1, 3.4), 3.0 (1.1, 8.1); and negative LR, 0.23 (0.03, 1.6), 0.66 (0.42, 1.0), respectively. In SROC curves, the area under the curve (AUC) was 0.81 (SE, 0.11) and 0.71 (SE, 0.13) and the Q* index was 0.74 and 0.66, respectively. [18F]FDG PET/CT had higher sensitivity, while DOR and SROC curves showed better diagnostic performance in [18F]FDG PET and PET/CT studies as compared to CT.

Keywords: GIST; PET/CT; [18F]FDG PET; molecular targeted therapy; treatment response assessment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram of included articles. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 2
Figure 2
Quality assessment of the included studies using Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2).
Figure 3
Figure 3
Forest plots (of sensitivity and specificity) of [18F]FDG PET or PET/CT and CT and pooled the diagnostic performance of the imaging techniques. For each test, we combined the SROC curves and their corresponding findings.
Figure 4
Figure 4
Summary receiver operating characteristic (SROC) curve for the diagnostic performance of [18F]FDG PET or PET/CT (black curve) and CT (red curve). The size of the circle diamond indicates the weight of each study in [18F]FDG PET or PET/CT and CT, respectively. The area under the SROC curve is 0.81 for [18F]FDG PET or PET/CT and 0.76 for CT.
See this image and copyright information in PMC

References

    1. Tran T., Davila J.A., El-Serag H.B. The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000. Am. J. Gastroenterol. 2005;100:162–168. doi: 10.1111/j.1572-0241.2005.40709.x. - DOI - PubMed
    1. Nilsson B., Bümming P., Meis-Kindblom J.M., Odén A., Dortok A., Gustavsson B., Sablinska K., Kindblom L.-G. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—A population-based study in western Sweden. Cancer. 2005;103:821–829. doi: 10.1002/cncr.20862. - DOI - PubMed
    1. Tzen C.-Y., Wang J.-H., Huang Y.-J., Wang M.-N., Lin P.-C., Lai G.-L., Wu C.-Y., Tzen C.-Y. Incidence of Gastrointestinal Stromal Tumor: A Retrospective Study Based on Immunohistochemical and Mutational Analyses. Dig. Dis. Sci. 2007;52:792–797. doi: 10.1007/s10620-006-9480-y. - DOI - PMC - PubMed
    1. Miettinen M., Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006;130:1466–1478. doi: 10.5858/2006-130-1466-GSTROM. - DOI - PubMed
    1. Miettinen M., Sobin L.H., Lasota J. Gastrointestinal Stromal Tumors of the Stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am. J. Surg. Pathol. 2005;29:52–68. doi: 10.1097/01.pas.0000146010.92933.de. - DOI - PubMed

LinkOut - more resources